Cargando…
Case Report: Early Treatment With Chenodeoxycholic Acid in Cerebrotendinous Xanthomatosis Presenting as Neonatal Cholestasis
Background: Cerebrotendinous xanthomatosis (CTX) is an inborn disorder of bile acid synthesis which causes progressive accumulation of toxic metabolites in various organs, particularly in brain and tendons. Most cases are diagnosed and treated in the second or third decade of life, when neurological...
Autores principales: | Degrassi, Irene, Amoruso, Chiara, Giordano, Giuseppe, Del Puppo, Marina, Mignarri, Andrea, Dotti, Maria Teresa, Naturale, Mauro, Nebbia, Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381104/ https://www.ncbi.nlm.nih.gov/pubmed/32766184 http://dx.doi.org/10.3389/fped.2020.00382 |
Ejemplares similares
-
The safety and effectiveness of chenodeoxycholic acid treatment in patients with cerebrotendinous xanthomatosis: two retrospective cohort studies
por: Verrips, Aad, et al.
Publicado: (2019) -
Cerebrotendinous xanthomatosis‐associated diarrhea and response to chenodeoxycholic acid treatment
por: Brass, Eric P., et al.
Publicado: (2020) -
Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid
por: Islam, Mahjabin, et al.
Publicado: (2021) -
Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment
por: Huidekoper, Hidde H., et al.
Publicado: (2015) -
Evaluation of the effect of chenodeoxycholic acid treatment on skeletal system findings in patients with cerebrotendinous xanthomatosis
por: Zübarioğlu, Tanyel, et al.
Publicado: (2019)